Inflammatory bowel disease

Medical Journal of Australia

Volumn 169, Issue 7, 1998, Pages 387-394

  Gibson, Peter R ^a,b,c   Anderson, Robert P ^d  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b Department of Gastroenterology ^*

^c UNIVERSITY OF MELBOURNE   (Australia)

^d RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OLSALAZINE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TINIDAZOLE;

AGRANULOCYTOSIS; BONE NECROSIS; CATARACT; COLONOSCOPY; CUSHINGOID SYNDROME; DIABETES MELLITUS; ENTERITIS; ENVIRONMENTAL FACTOR; FECES; FEVER; GROWTH RETARDATION; HEADACHE; HEMOLYSIS; HEPATITIS; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INTESTINE BIOPSY; INTRAOCULAR HYPERTENSION; MALE INFERTILITY; MENTAL DISEASE; NAUSEA; NEPHRITIS; NEUTROPENIA; OSTEOPOROSIS; PANCREATITIS; RASH; REVIEW; VERNER MORRISON SYNDROME; VOMITING;

EID: 0032487553     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb126811.x     Document Type: Review

References (25)

1. Lapidus A, Bernell O, Hellers G. et al. Incidence of Crohn's disease in Stockholm county 1855-1989. Gut 1997; 41: 480-486.
2. Langman MJS. Epidemiological overview of inflammatory bowel disease. In: Allan RN, Rhodes JM, Hanauer SB, et al, editors. Inflammatory bowel diseases. 3rd edition. New York: Churchill Livingstone, 1997: 35-39.
3. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-1854.
4. Sutherland LR, Romcharan S, Bryant HE, Pick G. Effect of cigarette smoking on risk of recurrence following resection for Crohn's disease. Gastroenterology 1990; 98: 1123-1128.
5. Timmer A, Sutherland LR, Martin F, et al. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. Gastroenterology 1998; 114: 1143-1150.
6. Tysk C, Lindberg E, Jarnerot G, Floderus Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29: 990-996.
7. Persson P-G, Bernell O, Leijonmarck C-E, et al. Survival and cause-specific mortality in inflammatory bowel disease: a population-based study. Gastroenterology 1996; 110: 1339-1345.
8. Selby W. The natural history of ulcerative colitis. Baillieres Clin Gastroenterol 1997; 11: 53-64.
9. Brzezinski A, Lashner BA. Natural history of Crohn's disease. In: Allan RN, Rhodes JM, Hanauer SB, et al, editors. Inflammatory bowel diseases. 3rd edition. New York: Churchill Livingstone, 1997: 463-474.
10. Weiss A, Mayer L. Extraintestinal manifestations of inflammatory bowel disease. In: Allan RN, Rhodes JM, Hanauer SB, et al, editors. Inflammatory bowel diseases. 3rd edition. New York: Churchill Livingstone, 1997: 623-632.
11. Mapstone NP, Dixon MF. Collagenous, microscopic and lymphocytic colitis. In: Allan RN, Rhodes JM, Hanauer SB, et al, editors. Inflammatory bowel diseases. 3rd edition. New York: Churchill Livingstone, 1997: 369-377.
12. Macrae FA, Bhathal PS. Colonoscopy and biopsy. Baillieres Clin Gastroenterol 1997; 11: 65-82.
13. Australian Crohn's Disease and Colitis Association. ACCA Newsletter 1995; 2 (May).
14. Ferguson A, Glen M, Ghosh S. Crohn's disease: nutrition and nutritional therapy. Baillieres Clin Gastroenterol 1998; 12: 93-114.
15. Allan RN, Rhodes JM, Hanauer SB, et al, editors. Inflammatory bowel diseases. 3rd edition. New York: Churchill Livingstone, 1997.
16. Forbes A. Clinician's guide to inflammatory bowel disease. London: Chapman & Hall Medical, 1997.
17. Piper DW, de Carle DJ, Talley NJ, et al. Gastrointestinal and hepatic diseases. In: Speight TM, Holford NHG, editors. Avery's drug treatment. 4th ed. Auckland: Adis International. 1997: 933-1021.
18. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. W Engl J Med 1994; 331: 842-845.
19. Richter F, Scheppach W. Innovations in topical therapy. Baillieres Clin Gastroenterol 1997; 11: 97-109.
20. McLeod RS, Cohen Z. Perineal Crohn's disease. Epidemiological overview of inflammatory bowel disease. In: Allan RN, Rhodes JM, Hanauer SB, et al, editors. Inflammatory bowel diseases, 3rd edition. New York: Churchill Livingstone, 1997.
21. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis, Inflamm Bowel Dis 1997; 3: 65-78.
22. Hawthorne AB, Logan FR, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis, BMJ 1992; 305: 20-22.
23. Camma C, Giunta M, Rosselli M, Cottone M. Mesalazine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465-1473.
24. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955-957.
25. Dean PA, Dozios RR. Surgical options - ileoanal pouch. In: Allan RN, Rhodes JM, Hanauer SB, et al, editors. Inflammatory bowel diseases 3rd edition. New York: Churchill Livingstone, 1997: 761-772.